Eaton Corporation plc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Eaton Corporation plc trades at $399.45 (market cap $166.36B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Eaton Corporation plc is far larger — about 18.8× Kymera Therapeutics Inc. Common Stock's market cap, and Eaton Corporation plc pays a 1.03% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 32 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| ETN | KYMR | |
|---|---|---|
Market Cap | $166.36B | $8.87B |
Volume | 1,762,788 | 779,107 |
Sector | Industrials | Health |
52-Week High | $459.96 | $127.31 |
52-Week Low | $315.82 | $55.80 |
Typical Hold Time | 32 Days | 0 Days |
Enterprise Value | $186.99B | $8.26B |
Dividend Yield | 1.03% | — |
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $428.31, up 0.38% on the day, with a neutral technical signal and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 12.75% and ROE of 19.71%. Recent news highlights growth from data center and aerospace demand, supported by strategic acquisitions like COL Group (Business Wire, 2026-09-25).
The outlook remains positive given analyst consensus with a $502.38 price target and 70% buy ratings. Key opportunities include exposure to AI-driven data center expansion and grid modernization. Risks involve execution of acquisitions, competitive pressures, and macroeconomic sensitivity. Valuation multiples like a P/E of 43.62 suggest premium pricing relative to earnings growth.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →